CDKN2A is a highly prevalent gene mutation in human cancers [36, 37], with three distinct mechanisms identified as potential contributors to its inactivation: genomic deletions, point mutations, and hypermethylation of the CDKN2A promoter region CpG island [38–40]. Here, CDKN2A is linked to cancer.